课题基金 / 基金详情

Preclinical imaging platform for assessing a novel anti-amyloid therapy

Preclinical imaging platform for assessing a novel anti-amyloid therapy
用于评估新型抗淀粉样蛋白疗法的临床前成像平台
批准号:
365455
负责人:
Kang Min Su
金额:
$7.65万
依托单位国家:
加拿大
项目类别:
Studentship Programs
财政年份:
2016
资助国家:
加拿大
项目状态:
已结题
起止时间:
2016-10-01 至 2019-10-01

项目摘要

项目成果

Kang Min Su的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Alzheimer's disease (AD) is a progressive neurodegenerative disease that is characterized by multiple pathologies of abnormal aggregates of misfolded proteins: amyloid beta (Ab) and neurofibrillary tangles (NFT). In 2014, the number of people living with
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Multi-scale characterization of molecular and connectomic vulnerability to AD pathology
Preclinical assessment of KAL-ABP target engagement and efficacy using PET, MRI and CSF biomarkers
Amyloid induced hippocampal metabolic network remodelling is associated with memory and cognitive dysfunction
Characterizing the effects of beta-amyloid aggregates on the hippocampal network in Alzheimer's Disease patients and animal models.
海外基金